Canavan disease (CD) is a neurological disorder caused by an interruption in the metabolism of N-acetylaspartate (NAA). Numerous mutations have been found in the enzyme that hydrolyzes NAA, and the catalytic activity of aspartoacylase is significantly impaired in CD patients. Recent studies have also supported an important role in CD for the enzyme that catalyzes the synthesis of NAA in the brain. However, previous attempts to study this enzyme had not succeeded in obtaining a soluble, stable and active form of this membrane-associated protein. We have now utilized fusion constructs with solubilizing protein partners to obtain an active and soluble form of aspartate N-acetyltransferase. Characterization of the properties of this enzyme has set the stage for the development of selective inhibitors that can lower the elevated levels of NAA that are observed in CD patients and potentially serve as a new treatment therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pep.2015.11.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The pathogenesis of, and pharmacological treatment for, Canavan disease.
Drug Discov Today
September 2022
Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD 21205, USA; Department of Pharmacology and Molecular Science, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD 21205, USA; Department of Oncology, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD 21205, USA; Department of Medicine, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD 21205, USA; Department of Psychiatry, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD 21205, USA. Electronic address:
Canavan disease (CD) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (ASPA). ASPA is highly expressed in oligodendrocytes and catalyzes the cleavage of N-acetylaspartate (NAA) to produce aspartate and acetate. In this review, we examine the pathologies and clinical presentation in CD, the metabolism and transportation of NAA in the brain, and the hypothetical mechanisms whereby ASPA deficiency results in dysmyelination and a failure of normal brain development.
View Article and Find Full Text PDFThe cAMP Inducers Modify -Acetylaspartate Metabolism in Wistar Rat Brain.
Antioxidants (Basel)
September 2021
Department of Molecular Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland.
Neuronal -acetylaspartate production appears in the presence of aspartate -acetyltransferase (NAT8L) and binds acetyl groups from acetyl-CoA with aspartic acid. Further -acetylaspartate pathways are still being elucidated, although they seem to involve neuron-glia crosstalk. Together with -acetylaspartate, NAT8L takes part in oligoglia and astroglia cell maturation, myelin production, and dopamine-dependent brain signaling.
View Article and Find Full Text PDFHigh Throughput Screening Cascade To Identify Human Aspartate -Acetyltransferase (ANAT) Inhibitors for Canavan Disease.
ACS Chem Neurosci
September 2021
Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.
Canavan disease (CD) is a progressive, fatal neurological disorder that begins in infancy resulting from a mutation in aspartoacyclase (ASPA), an enzyme that catalyzes the deacetylation of -acetyl aspartate (NAA) into acetate and aspartate. Increased NAA levels in the brains of affected children are one of the hallmarks of CD. Interestingly, genetic deletion of -acetyltransferase-8-like (NAT8L), which encodes aspartate -aceyltransferase (ANAT), an enzyme responsible for the synthesis of NAA from l-aspartate and acetyl-CoA, leads to normalization of NAA levels and improvement of symptoms in several genetically engineered mouse models of CD.
View Article and Find Full Text PDFEngineering of a critical membrane-anchored enzyme for high solubility and catalytic activity.
Arch Biochem Biophys
May 2021
Department of Chemistry & Biochemistry, University of Toledo, Toledo, OH, 43606, USA. Electronic address:
Membrane-associated proteins carry out a wide range of essential cellular functions but the structural characterization needed to understand these functions is dramatically underrepresented in the Protein Data Bank. Producing a soluble, stable and active form of a membrane-associated protein presents formidable challenges, as evidenced by the variety of approaches that have been attempted with a multitude of different membrane proteins to achieve this goal. Aspartate N-acetyltransferase (ANAT) is a membrane-anchored enzyme that performs a critical function, the synthesis of N-acetyl-l-aspartate (NAA), the second most abundant amino acid in the brain.
View Article and Find Full Text PDFNeither Excessive Nitric Oxide Accumulation nor Acute Hyperglycemia Affects the -Acetylaspartate Network in Wistar Rat Brain Cells.
Int J Mol Sci
November 2020
Department of Molecular Medicine, Medical University of Gdansk, 80-211 Gdansk, Poland.
The -acetylaspartate network begins in neurons with -acetylaspartate production catalyzed by aspartate -acetyltransferase from acetyl-CoA and aspartate. Clinical studies reported a significant depletion in -acetylaspartate brain level in type 1 diabetic patients. The main goal of this study was to establish the impact of either hyperglycemia or oxidative stress on the -acetylaspartate network.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!